Medtronic sees rebound in elective procedures as Omicron surge wanes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Medtronic, Inc. (MDT) PT Lowered to $124 at Needham & Company
February 22, 2022 1:59 PM ESTNeedham & Company analyst Michael Matson lowered the price target on Medtronic, Inc. (NYSE: MDT) to $124.00 (from $128.00) while maintaining a Buy rating following earnings.
The analyst commented, "MDT's F3Q22 revenue missed consensus while its EPS beat consensus and organic revenue growth slowed... More
